Zebrafi sh as a model for human osteosarcoma

Advances in Experimental Medicine and Biology

Volumn 804, Issue , 2014, Pages 221-236

  Mohseny, A B ^a   Hogendoorn, P C W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Bone tumor; Drug screening; Fish; Immune system; Metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EZRIN; METHOTREXATE; MURAMYL TRIPEPTIDE; IMMUNOLOGIC FACTOR; TUMOR PROTEIN; ZEBRAFISH PROTEIN;

ARTICLE; CANCER INHIBITION; CANCER MODEL; CANCER SURGERY; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNE RESPONSE; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; STEM CELL NICHE; TUMOR GROWTH; ZEBRA FISH; ANIMAL; ANIMAL EMBRYO; BONE DEVELOPMENT; BONE TUMOR; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PRENATAL DEVELOPMENT; REVIEW; ROBOTICS; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; EMBRYO, NONMAMMALIAN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOLOGIC FACTORS; NEOPLASM PROTEINS; OSTEOGENESIS; OSTEOSARCOMA; ROBOTICS; SIGNAL TRANSDUCTION; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 84907168939     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-04843-7_12     Document Type: Article

References (95)

1. Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteo-sarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20(3):776–790
2. Lewis IJ, Nooij MA, Whelan J et al (2007) Improvement in histologic response but not survival in osteosarcoma patients treated with intensifi ed chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99(2):112–128
3. Sandberg AA, Bridge JA (2003) Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet 145(1):1–30
4. Cleton-Jansen AM, Buerger H, Hogendoorn PCW (2005) Central high-grade osteosarcoma of bone: diagnostic and genetic considerations. Curr Diagn Pathol 11:390–399
5. Stoletov K, Klemke R (2008) Catch of the day: zebrafi sh as a human cancer model. Oncogene 27(33):4509–4520
6. Deo RC, MacRae CA (2011) The zebrafi sh: scalable in vivo modeling for systems biology. Wiley Interdiscip Rev Syst Biol Med 3(3):335–346
7. Merlino G, Khanna C (2007) Fishing for the origins of cancer. Genes Dev 21(11):1275–1279
8. Langenau DM, Keefe MD, Storer NY et al (2007) Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev 21(11):1382–1395
9. Feitsma H, Kuiper RV, Korving J et al (2008) Zebrafi sh with mutations in mismatch repair genes develop neurofi bromas and other tumors. Cancer Res 68(13):5059–5066
10. Etchin J, Kanki JP, Look AT (2011) Zebrafi sh as a model for the study of human cancer. Methods Cell Biol 105:309–337
11. He S, Krens SG, Zhan H et al (2011) A DeltaRaf1-ER-inducible oncogenic zebrafi sh liver cell model identifi es hepatocellular carcinoma signatures. J Pathol 225(1):19–28
12. Bridge JA, Nelson M, McComb E et al (1997) Cytogenetic fi ndings in 73 osteosarcoma specimens and a review of the literature. Cancer Genet Cytogenet 95(1):74–87
13. Rosenberg AE, Cleton-Jansen AM, Gd P et al (2013) Conventional osteosarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (eds) WHO classifi cation of tumours of soft tissue and bone. IARC, Lyon, pp 282–289
14. Kuijjer ML, Hogendoorn PC, Cleton-Jansen AM (2013) Genome-wide analyses on high-grade osteo-sarcoma: making sense of a genomically most unstable tumor. Int J Cancer 133(11):2512–2521
15. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5): 646–674
16. Mohseny AB, Hogendoorn PC (2011) Concise review: mesenchymal tumors: when stem cells go mad. Stem Cells 29(3):397–403
17. Stephens PJ, Greenman CD, Fu B et al (2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144(1):27–40
18. Forment J V, Kaidi A, Jackson SP (2012) Chromothripsis and cancer: causes and consequences of chromosome shattering. Nat Rev Cancer 12(10):663–670
19. Davoli T, de Lange T (2012) Telomere-driven tetraploidization occurs in human cells undergoing crisis and promotes transformation of mouse cells. Cancer Cell 21(6):765–776
20. Gohring G, Lange K, Hofmann W et al (2012) Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide. Leukemia 26(2):356–358
21. Stoletov K, Montel V, Lester RD et al (2007) High-resolution imaging of the dynamic tumor cell vascular interface in transparent zebrafi sh. Proc Natl Acad Sci U S A 104(44): 17406–17411
22. Lee LM, Seftor EA, Bonde G et al (2005) The fate of human malignant melanoma cells transplanted into zebrafi sh embryos: assessment of migration and cell division in the absence of tumor formation. Dev Dyn 233(4):1560–1570
23. Herbomel P, Thisse B, Thisse C (1999) Ontogeny and behaviour of early macrophages in the zebrafi sh embryo. Development 126(17):3735–3745
24. Lam SH, Chua HL, Gong Z et al (2004) Development and maturation of the immune system in zebrafi sh, Danio rerio: a gene expression profi ling, in situ hybridization and immunological study. Dev Comp Immunol 28(1):9–28
25. Tolar J, Nauta AJ, Osborn MJ et al (2007) Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 25(2):371–379
26. Mohseny AB, Szuhai K, Romeo S et al (2009) Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 219(3): 294–305
27. Mohseny AB, Xiao W, Carvalho R et al (2012) An osteosarcoma zebrafi sh model implicates Mmp-19 and Ets-1 as well as reduced host immune response in angiogenesis and migration. J Pathol 227(2):245–253
28. Marques IJ, Weiss FU, Vlecken DH et al (2009) Metastatic behaviour of primary human tumours in a zebrafi sh xenotransplantation model. BMC Cancer 9:128
29. White RM, Sessa A, Burke C et al (2008) Transparent adult zebrafi sh as a tool for in vivo transplantation analysis. Cell Stem Cell 2(2):183–189
30. Mayordomo E, Machado I, Giner F et al (2010) A tissue microarray study of osteosarcoma: histopathologic and immunohistochemical validation of xenotransplanted tumors as preclini-cal models. Appl Immunohistochem Mol Morphol 18(5):453–461
31. Mohseny AB, Machado I, Cai Y et al (2011) Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest 91(8): 1195–1205
32. Rauta PR, Nayak B, Das S (2012) Immune system and immune responses in fi sh and their role in comparative immunity study: a model for higher organisms. Immunol Lett 148(1):23–33
33. van der Vaart M, van Soest JJ, Spaink HP et al (2013) Functional analysis of a zebrafi sh myd88 mutant identifi es key transcriptional components of the innate immune system. Dis Model Mech 6(3):841–854
34. Press CMCL, Evensen O (1999) The morphology of the immune system in teleost fi shes. Fish Shellfi sh Immunol 9:309–318
35. Bromage ES, Kaattari IM, Zwollo P et al (2004) Plasmablast and plasma cell production and distribution in trout immune tissues. J Immunol 173(12):7317–7323
36. Zwollo P, Cole S, Bromage E et al (2005) B cell heterogeneity in the teleost kidney: evidence for a maturation gradient from anterior to posterior kidney. J Immunol 174(11):6608–6616
37. Zwollo P, Haines A, Rosato P et al (2008) Molecular and cellular analysis of B-cell populations in the rainbow trout using Pax5 and immunoglobulin markers. Dev Comp Immunol 32(12):1482–1496
38. Zwollo P, Mott K, Barr M (2010) Comparative analyses of B cell populations in trout kidney and mouse bone marrow: establishing “B cell signatures”. Dev Comp Immunol 34(12): 1291–1299
39. Brattgjerd S, Evensen O (1996) A sequential light microscopic and ultrastructural study on the uptake and handling of Vibrio salmonicida in phagocytes of the head kidney in experimentally infected Atlantic salmon (Salmo salar L.). Vet Pathol 33(1):55–65
40. Kaattari SL, Irwin MJ (1985) Salmonid spleen and anterior kidney harbor populations of lymphocytes with different B cell repertoires. Dev Comp Immunol 9(3):433–444
41. Manning MJ, Nakanishi T (1996) The specifi c immune system: cellular defense. The fi sh immune system. Organism, pathogen and environment. Academic, San Diego, CA
42. Press CM, Dannevig BH, Landsverk T (1994) Immune and enzyme histochemical phenotypes of lymphoid and nonlymphoid cells within the spleen and head kidney of Atlantic salmon. Fish Shellfi sh Immunol 4(2):79–93
43. Bowden TJ, Cook P, Rombout JHMW (2005) Development and function of the thymus in teleosts. Fish Shellfi sh Immunol 19:413–427
44. Hall C, Flores M V, Storm T et al (2007) The zebrafi sh lysozyme C promoter drives myeloid-specifi c expression in transgenic fi sh. BMC Dev Biol 7:42
45. Bayne CJ, Gerwick L (2001) The acute phase response and innate immunity of fi sh. Dev Comp Immunol 25(8–9):725–743
46. Carroll MC (2004) The complement system in regulation of adaptive immunity. Nat Immunol 5(10):981–986
47. Carroll MC (2004) The complement system in B cell regulation. Mol Immunol 41(2–3): 141–146
48. Holland JW, Pottinger TG, Secombes CJ (2002) Recombinant interleukin-1 beta activates the hypothalamic-pituitary-interrenal axis in rainbow trout, Oncorhynchus mykiss. J Endocrinol 175(1):261–267
49. Du Pasquier L (2001) The immune system of invertebrates and vertebrates. Comp Biochem Physiol B Biochem Mol Biol 129(1):1–15
50. Fischer U, Utke K, Somamoto T et al (2006) Cytotoxic activities of fi sh leucocytes. Fish Shellfi sh Immunol 20(2):209–226
51. Zou J, Grabowski PS, Cunningham C et al (1999) Molecular cloning of interleukin 1beta from rainbow trout Oncorhynchus mykiss reveals no evidence of an ice cut site. Cytokine 11(8):552–560
52. Bird S, Wang T, Zou J et al (2002) The fi rst cytokine sequence within cartilaginous fi sh: IL-1 beta in the small spotted catshark (Scyliorhinus canicula). J Immunol 168(7):3329–3340
53. Roca FJ, Mulero I, Lopez-Munoz A et al (2008) Evolution of the infl ammatory response in vertebrates: fi sh TNF-alpha is a powerful activator of endothelial cells but hardly activates phagocytes. J Immunol 181(7):5071–5081
54. Wang T, Secombes CJ (2009) Identifi cation and expression analysis of two fi sh-specifi c IL-6 cytokine family members, the ciliary neurotrophic factor (CNTF)-like and M17 genes, in rainbow trout Oncorhynchus mykiss. Mol Immunol 46(11–12):2290–2298
55. Lee MS, Kim YJ (2007) Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem 76:447–480
56. Renshaw SA, Trede NS (2012) A model 450 million years in the making: zebrafi sh and vertebrate immunity. Dis Model Mech 5(1):38–47
57. Mione M, Meijer AH, Snaar-Jagalska BE et al (2009) Disease modeling in zebrafi sh: cancer and immune responses – a report on a workshop held in Spoleto, Italy, July 20–22, 2009. Zebrafi sh 6(4):445–451
58. Chang T Y, Pardo-Martin C, Allalou A et al (2012) Fully automated cellular-resolution vertebrate screening platform with parallel animal processing. Lab Chip 12(4):711–716
59. Spaink HP, Cui C, Wiweger MI et al (2013) Robotic injection of zebrafi sh embryos for high-throughput screening in disease models. Methods 62(3):246–254
60. Truong HH, de Sonneville J, Ghotra VP et al (2012) Automated microinjection of cell- polymer suspensions in 3D ECM scaffolds for high-throughput quantitative cancer invasion screens. Biomaterials 33(1):181–188
61. Amatruda JF, Shepard JL, Stern HM et al (2002) Zebrafi sh as a cancer model system. Cancer Cell 1(3):229–231
62. Smolowitz R, Hanley J, Richmond H (2002) A three-year retrospective study of abdominal tumors in zebrafi sh maintained in an aquatic laboratory animal facility. Biol Bull 203(2):265–266
63. Stern HM, Zon LI (2003) Cancer genetics and drug discovery in the zebrafi sh. Nat Rev Cancer 3(7):533–539
64. Berghmans S, Jette C, Langenau D et al (2005) Making waves in cancer research: new models in the zebrafi sh. Biotechniques 39(2):227–237
65. Goessling W, North TE, Zon LI (2007) New waves of discovery: modeling cancer in zebrafi sh. J Clin Oncol 25(17):2473–2479
66. Berghmans S, Murphey RD, Wienholds E et al (2005) tp53 mutant zebrafi sh develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci U S A 102(2):407–412
67. Kari G, Rodeck U, Dicker AP (2007) Zebrafi sh: an emerging model system for human disease and drug discovery. Clin Pharmacol Ther 82(1):70–80
68. Peng K, Cui C, Tomatsu I et al (2010) Dextran based photodegradable hydrogels formed via a Michael addition. Soft Matter 7:4881–4887
69. Khanna C, Wan X, Bose S et al (2004) The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10(2):182–186
70. Bulut G, Hong SH, Chen K et al (2012) Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene 31(3):269–281
71. Anninga JK, Gelderblom H, Fiocco M et al (2011) Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer 47(16):2431–2445
72. Chou AJ, Kleinerman ES, Krailo MD et al (2009) Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Cancer 115(22):5339–5348
73. Buddingh EP, Schilham MW, Ruslan SE et al (2011) Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother 60(4):575–586
74. Lehner M, Gotz G, Proff J et al (2012) Redirecting T cells to Ewing’s sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA trans-fection. PLoS One 7(2):e31210
75. Ahn YO, Weigel B, Verneris MR (2010) Killing the killer: natural killer cells to treat Ewing’s sarcoma. Clin Cancer Res 16(15):3819–3821
76. Ganeshkumar M, Sathishkumar M, Ponrasu T et al (2013) Spontaneous ultra fast synthesis of gold nanoparticles using Punica granatum for cancer targeted drug delivery. Colloids Surf B Biointerfaces 106:208–216
77. Hagner N, Joerger M (2010) Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res 2:293–301
78. Walkley CR, Qudsi R, Sankaran VG et al (2008) Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev 22(12): 1662–1676
79. Parant JM, George SA, Holden JA et al (2010) Genetic modeling of Li-Fraumeni syndrome in zebrafi sh. Dis Model Mech 3(1–2):45–56
80. Mohseny AB (2008) Bone: conventional osteosarcoma. Atlas Genet Cytogenet Oncol Haematol. http://AtlasGeneticsOncology.org/Tumors/ConvOsteoID5344.html
81. Mohseny AB, Tieken C, van der Velden PA et al (2010) Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma. Genes Chromosomes Cancer 49(12):1095–1103
82. Savage SA, Mirabello L, Wang Z et al (2013) Genome-wide association study identifi es two susceptibility loci for osteosarcoma. Nat Genet 45(7):799–803
83. Bedell VM, Wang Y, Campbell JM et al (2012) In vivo genome editing using a high-effi ciency TALEN system. Nature 491(7422):114–118
84. Bill BR, Petzold AM, Clark KJ et al (2009) A primer for morpholino use in zebrafi sh. Zebrafi sh 6(1):69–77
85. Cade L, Reyon D, Hwang WY et al (2012) Highly effi cient generation of heritable zebrafi sh gene mutations using homo- and heterodimeric TALENs. Nucleic Acids Res 40(16): 8001–8010
86. Chen S, Oikonomou G, Chiu CN et al (2013) A large-scale in vivo analysis reveals that TALENs are signifi cantly more mutagenic than ZFNs generated using context-dependent assembly. Nucleic Acids Res 41(4):2769–2778
87. Clark KJ, Voytas DF, Ekker SC (2011) A TALE of two nucleases: gene targeting for the masses? Zebrafi sh 8(3):147–149
88. Dahlem TJ, Hoshijima K, Jurynec MJ et al (2012) Simple methods for generating and detecting locus-specifi c mutations induced with TALENs in the zebrafi sh genome. PLoS Genet 8(8):e1002861
89. Huang P, Zhu Z, Lin S et al (2012) Reverse genetic approaches in zebrafi sh. J Genet Genomics 39(9):421–433
90. Moore FE, Reyon D, Sander JD et al (2012) Improved somatic mutagenesis in zebrafi sh using transcription activator-like effector nucleases (TALENs). PLoS One 7(5):e37877
91. Leacock SW, Basse AN, Chandler GL et al (2012) A zebrafi sh transgenic model of Ewing’s sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis. Dis Model Mech 5(1):95–106
92. Onnebo SM, Condron MM, McPhee DO et al (2005) Hematopoietic perturbation in zebrafi sh expressing a tel-jak2a fusion. Exp Hematol 33(2):182–188
93. de Andrea CE, Prins FA, Wiweger MI et al (2011) Growth plate regulation and osteochon-droma formation: insights from tracing proteoglycans in zebrafi sh models and human cartilage. J Pathol 224(2):160–168
94. Wiweger MI, Avramut CM, de Andrea CE et al (2011) Cartilage ultrastructure in proteoglycan-defi cient zebrafi sh mutants brings to light new candidate genes for human skeletal disorders. J Pathol 223(4):531–542
95. Wiweger MI, Zhao Z, van Merkesteyn RJ et al (2012) HSPG-defi cient zebrafi sh uncovers dental aspect of multiple osteochondromas. PLoS One 7(1):e29734